Weil represents the Audit Committee of the Board of Directors of American Realty Capital Properties (n/k/a VEREIT), a publicly-traded real estate investment trust, to conduct an internal investigation of allegations of accounting irregularities. The investigation resulted in a restatement and the separation from the company of several top executives. A multi-disciplinary Weil team advised the Audit Committee and the Board of Directors with respect to all aspects of the investigation and the resulting fallout. Weil continues to represent the Audit Committee members in connection with related shareholder litigation.

Weil represents a former senior trader at a major financial institution in connection with the U.S. Department of Justice’s criminal investigation into alleged manipulation of LIBOR.

Weil served as lead counsel overseeing the defense of Toyobo, a major Japanese fiber manufacturer, in connection with False Claims Act litigation brought by the U.S. DOJ, class action litigation, multiple personal injury suits, and claims by multiple state attorneys general and foreign states, among others, relating to the performance of Toyobo’s Zylon fiber in bullet-resistant vests used by thousands of law enforcement agencies worldwide. In 2018, Weil negotiated a settlement of all remaining claims after securing a number of successful outcomes in the various lawsuits.

Weil represented AIG in connection with inquiries by federal, state and international agencies, including the U.S. Securities and Exchange Commission, the U.S. Department of Justice, multiple state attorney generals’ offices, the U.S. Office of the Special Inspector General for the Troubled Asset Relief Program, the U.K. Serious Fraud Office, the U.K. Financial Services Authority, as well as numerous inquiries by various Senate and House committees and congressionally-appointed commissions and panels, including the Financial Crisis Inquiry Commission and the Congressional Oversight Panel, arising out of AIG’s subprime related losses, AIG’s receipt of emergency funding by the federal government in late 2008, and compensation issues that have been the subject of much national media attention.

Weil is representing a number of major companies in a variety of sensitive regulatory investigations, including:

• An SEC investigation into a failed IPO of an electronic trading platform
• An SEC investigation and related class action litigation involving the underwriting of a SaaS provider
• A CFTC investigation into a conspiracy to manipulate the ISDAFix, the International Swaps and Derivatives Association’s benchmark rate for the swaps market

Weil is advising a global pharmaceutical company in connection with DOJ and SEC investigations of alleged violations of the FCPA involving the company’s subsidiaries in a number of countries in emerging markets. In 2018, Weil secured a declination when the DOJ closed its investigation without bringing an enforcement action.

Weil represents a major healthcare provider in connection with an investigation into alleged False Claims Act violations.